Document:

Exhibit 10.2

 

AMENDMENT TO REAL ESTATE PURCHASE

AND SALE AGREEMENT  

 

THIS AMENDMENT TO REAL
ESTATE PURCHASE AND SALE AGREEMENT (this “Amendment”) is made and entered into as of February 1, 2019, by and
between SIGNATURE HOLDINGS, LLC, WRG INVESTMENTS, LLC, FOSTER SIGNATURE INVESTMENTS, LLC, AND LONE OAK RUN INVESTMENT HOLDINGS,
LLC (collectively, “Seller”), and REVEN HOUSING FUNDING 2, LLC, a Delaware limited liability company (“Buyer”).

  

RECITALS:

 

WHEREAS, Seller
and Buyer are parties to that certain Real Estate Purchase and Sale Agreement November 28, 2018 (the “Contract”),
pursuant to which Seller agreed to sell to Buyer certain real property consisting of 45 single family homes in the State of Oklahoma,
as more particularly described in the Contract, together with all of the improvements and structures located thereon, any heating
and ventilating systems and other fixtures located therein or thereon, and all rights, interests, benefits, privileges, easements
and appurtenances to the land and the Improvements, if any (collectively, the “Premises”);

 

WHEREAS, Buyer
previously purchased 27 of the single family homes comprising the Premises; and

 

WHEREAS, Seller
and Buyer desire to amend the Contract in certain respects, all as more particularly described hereinbelow.

 

AGREEMENT:

 

NOW, THEREFORE,
in consideration of the mutual promises and covenants contained in the Contract, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged by each of the parties, Seller and Buyer hereby agree as follows:

 

1.       Seller
and Buyer hereby stipulate and agree that, of the 18 single family homes comprising the Premises that have not been previously
acquired by Buyer, six (6) of such single family homes are being excluded from the transaction contemplated under the Contract,
and those certain one (1) single family homes identified and generally described on Exhibit A attached to this Amendment
(the “Remaining Homes”), together with all of the Improvements (as defined in the Contract), any heating and
ventilating systems and other fixtures located therein or thereon, and all rights, interests, benefits, privileges, easements
and appurtenances to the land and the Improvements, if any, remain to be purchased by Buyer under the Contract.

 

2.       The
Contract is hereby amended to provide that the Purchase Price for the Remaining Homes shall mean $178,799.00, subject to adjustments
in accordance with the provisions of the Contract.

 

3.       Notwithstanding
anything contained in the Contract to the contrary, Buyer shall have the right to designate Reven Housing REIT OP, LP (“Affiliate”),
which is an affiliate of Buyer, as the party to acquire title to the certain single family home indicated on Exhibit A attached
hereto, in which event all documents to be delivered by Seller and Buyer with respect to the closing of such single family home,
including without limitation, the deed to be delivered by Seller, shall be for the benefit of Affiliate.

 

4.       All
capitalized terms found in the Contract shall have the same meaning when used in this Amendment. This Amendment may be executed
by facsimile or electronic signatures, which for all purposes shall be deemed to constitute originals. In addition, this Amendment
may be executed simultaneously in two or more counterparts, each of which shall be deemed an original and all of which together
shall constitute one instrument.

 

     

     

    

 

5.       Except
as amended hereby, all terms and provisions of the Contract are and remain in full force and effect as therein written and are
reinstated, ratified, and/or confirmed if and to the extent required to affirm the continuing validity of the Contract.

 

6.       In
the event of a conflict between the terms of this Amendment and those of the Contract, the terms of this Amendment shall govern
and control.

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be executed as of the day and year first above written.

 

 

	 	SELLER	 
	 	 	 	 
	 	SIGNATURE HOLDINGS, LLC	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Richard Foster	 
	 	 	Richard Foster	 
	 	 	Manager	 
	 	 	 	 
	 	WRG Investments, LLC	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Richard Foster	 
	 	 	Richard Foster	 
	 	 	Manager	 
	 	 	 	 
	 	Foster Signature Investments, LLC 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Richard Foster	 
	 	 	Richard Foster	 
	 	 	Manager	 
	 	 	 	 
	 	Lone Oak Run Investment Holdings, LLC
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Richard Foster	 
	 	 	Richard Foster	 
	 	 	Manager	 
	 	 	 	 
	 	 	 	 
	 	BUYER	 
	 	 	 	 
	 	REVEN HOUSING FUNDING 2, LLC, 	 
	 	a Delaware limited liability company	 
	 	 	 	 
	 	 	 	 
	 	By:	/s/ Chad Carpenter	 
	 	 	Chad Carpenter	 
	 	 	Chief Executive OfficerExhibit
10.1

 

Amendment
No. 2 to

SHARE
EXCHANGE AGREEMENT

Dated
as of January 31, 2019

 

This
Amendment No. 2 to Share Exchange Agreement (this “Amendment”) is entered into as of the date first set forth above
by and between (i) Novo Integrated Sciences, Inc., a Nevada corporation (the “Parent”); (ii) Novo Healthnet Limited,
a limited company incorporated under the Laws (as defined below) of the Province of Ontario, Canada (“NHL” and together
with the Parent, the “Buyer”) and (iii) CannaPiece Group Inc., an Ontario, Canada corporation (“CPG”,
“Seller”). Each of the Parent, NHL and CPG may be referred to herein collectively as the “Parties” and
separately as a “Party.

 

WHEREAS,
the Parent, NHL and CPG are parties to that certain Share Exchange Agreement dated as of December 18. 2018 (the “Original
Agreement”); and

 

WHEREAS,
on January 7, 2019, the Parties amended Section 2.02 (b) of the Original Agreement (“Amendment #1”) as follows:

 

(a)
Section 2.02(b) of the Original Agreement is hereby amended in its entirety to provide as follows: “The Subscription Agreements
value will be CAD $5,000,000 in the aggregate (the “Investment”). The Subscription Agreements for the total Investment
will be executed and delivered by CPG, together with payment of the applicable subscription funds, by no later than January 31,
2019.”

 

WHEREAS,
the Parties now desire to amend the Original Agreement and Amendment #1 as set forth herein;

 

NOW
THEREFORE, on the stated premises and for and in consideration of the mutual covenants and agreements hereinafter set forth and
the mutual benefits to the Parties to be derived herefrom, and intending to be legally bound hereby, it is hereby agreed as follows:

 

	 	2.	Definitions. Defined terms used herein without
definition shall have the meaning given them in the Original Agreement.

 

	 	3.	Amendment.

 

(a)
Section 2.02(b) of the Original Agreement and Amendment #1 are hereby amended in its entirety to provide as follows: “The
Subscription Agreements value will be CAD $5,000,000 in the aggregate (the “Investment”). The Subscription Agreements
for the total Investment will be executed and delivered by CPG, together with payment of the applicable subscription funds, by
no later than February 28, 2019.”

 

	 	4.	Miscellaneous.

 

	 	(a)	Other than as amended herein, the Original Agreement
and Amendment #1 shall remain in full force and effect.
	 	 	 
	 	(b)	This Amendment #2 shall be governed by, enforced, and
construed under and in accordance with the Laws of the State of Nevada, without giving effect to the principles of conflicts of
law thereunder. Each of the Parties (a) irrevocably consents and agrees that any legal or equitable action or proceedings arising
under or in connection with this Amendment #2 shall be brought exclusively in the state or federal courts of the United States
with jurisdiction in Palm Beach County, Florida. By execution and delivery of this Amendment #2, each Party hereto irrevocably
submits to and accepts, with respect to any such action or proceeding, generally and unconditionally, the jurisdiction of the
aforesaid courts, and irrevocably waives any and all rights such Party may now or hereafter have to object to such jurisdiction.
	 	 	 
	 	(c)	The headings contained in this Amendment #2 are intended
solely for convenience and shall not affect the rights of the Parties.
	 	 	 
	 	(d)	This Amendment #2 may be executed in multiple counterparts,
each of which shall be deemed an original and all of which taken together shall be but a single instrument. The execution and
delivery of a facsimile or other electronic transmission of a signature to this Amendment #2 shall constitute delivery of an executed
original and shall be binding upon the person whose signature appears on the transmitted copy.

 

[Signatures
Appear on Following Page]

 

    	 	 	 

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the date first-above written.

 

	 	Novo Integrated Sciences, Inc.
	 	 	 
	 	By: 	/s/ Robert Mattacchione
	 	Name:	Robert Mattacchione
	 	Title: 	Chief Executive Officer
	 	 	 
	 	Novo Healthnet Limited
	 	 	 
	 	By: 	/s/ Dr. Pierre Dalcourt
	 	Name: 	Dr. Pierre Dalcourt
	 	Title: 	President
	 	 	 
	 	CannaPiece Group Inc.
	 	 	 
	 	By: 	/s/ Ahmad Rasouli
	 	Name: 	Ahmad Rasouli
	 	Title:	CEOExhibit
10.2

 

Novo
Integrated Sciences Inc./ Novo Healthnet Limited

11120
NE 2nd Street, Suite 200

Bellevue,
Washington 98004

 

February
4, 2019

 

Pulse
Rx LTC Pharmacy

111
Zenway Blvd., Suite #3

Woodbridge,
Ontario

Canada,
L4H 3H9

 

Attention:
Martin Kusmirek

 

Re:
Letter of Intent for the Acquisition by Novo Healthnet Limited of 100% of the issued and outstanding equity stock of Pulse Rx
Inc.

 

This
binding letter of intent (“LOI” or “Letter”), is to generally record terms and conditions
of the proposed agreement whereby Novo Integrated Sciences Inc., a Nevada corporation (“NVOS”) and Novo Healthnet
Limited, a wholly owned Canadian subsidiary of NVOS (“NHL”) will acquire all of the issued and outstanding
shares of Pulse Rx Inc. (“Pulse”), a limited company incorporated under the laws of Ontario, operating as Pulse
Rx LTC Pharmacy, (the “Transaction”). This Letter represents only our good-faith intention to negotiate and enter
into a definitive agreement in a form acceptable to NVOS and Pulse.

 

This
Letter is a binding agreement between us. Notwithstanding the foregoing, the parties acknowledge and confirm it is their intention
that this Letter will serve only as a preliminary interim agreement in relation to the matters described herein, which will apply
until the Definitive Agreement (as defined below) is concluded.

 

Statements
below as to what we, or you, will do, or agree to do, or the like, are so expressed for convenience only, and are understood in
all instances (except for the items identified below in Section 11) to be subject to our mutual continued willingness to proceed
with the Transaction.

 

The
following paragraphs reflect our preliminary agreement with respect to the Transaction (as defined below):

 

1.
Structure: The parties intend to enter into a share exchange or other similar business combination in which:

 

(i)
NVOS will issue, based on a valuation of Pulse purchase price of $6 million CAD, the equivalent in capital stock based on the
30-trading day average share price in exchange for the shares of NHL issued pursuant to the Transaction. The issued shares will
be subject to a two-year lock up coinciding with the claw-back identified in Item 1.viii of this Agreement. In the event the claw-back
is waived prior to the two-year claw-back term, the lock-up will be removed and normal rule 144 restrictions will apply.

 

(ii)
For the sake of clarity; the current shareholder structure is referenced in our filings.

 

(iii)
Upon completion of the Transaction, Pulse shall have been advanced a loan in an amount not to exceed $6 million CAD, with the
use and disbursement of funds to be itemized pursuant to the definitive agreement and NVOS will hold all the issued and outstanding
shares of Pulse and Pulse shall be the wholly-owned subsidiary of NVOS or NHL, as determined in the definitive agreement.

 

    	 	 	 

    	 

    

 

(iv)
Pulse will have the right to appoint a board member to the board of directors of NVOS.

 

(v)
Performance bonuses related to proprietary SOPs and other Pulse intellectual property will be identifiable in a definitive agreement.

 

(vi)
The undersigned principal of Pulse shall enter into an employment agreement for a period of no less than two years from the close
of the Transaction. The employment agreement will identify specific bonus structures related to subsidiary revenue performance
as well as total corporate performance.

 

(vii)
The vendor(s) has the right to exercise a ‘claw-back’ within a two-year period commencing the date of the closing
of this transaction. The claw-back will result in the mutual return of Pulse and NVOS shares, which shares were the subject of
a share exchange, to the respective parties should targets not be met by NVOS as identified in a definitive agreement.

 

2.
Due Diligence: The parties will work promptly to carry out all required due diligence in respect of the proposed Transaction
including without limitation, the completion of standard business, legal and other inquiries and a review of applicable laws and
regulations. The parties will afford each other, its employees, auditors, legal counsel, and other authorized representatives
all reasonable opportunity and access during normal business hours to inspect and investigate the business and financial affairs
of the other party.

 

3.
Definitive Agreement. We mutually agree to proceed reasonably and in good faith toward the negotiation and execution of definitive
documentation which shall contain the terms and conditions set out in the LOI and such other terms, conditions, indemnities, representations,
warranties, covenants as are customary for transactions of this nature (the “Definitive Agreement”). The parties
shall cooperate in structuring the Transaction in the most effective manner having regard to applicable tax, corporate, and securities
laws. Upon the execution and delivery of the Definitive Agreement, it will supersede this Letter.

 

4.
Regulatory Approvals and Contractual Consents: Each of the parties will use its commercially reasonable best efforts to obtain:

 

(i).
the necessary board approvals and shareholder approvals for the Transaction prior to the execution of the Definitive Agreement;
and

 

(ii).
all necessary regulatory approvals (including approvals from any licensing authorities) and third-party consents and the necessary
shareholder approvals prior to the closing of the Transaction and to cooperate in providing any submissions necessary to affect
the Transaction.

 

5.
Other Conditions. The Definitive Agreement shall include, but will not be limited to, the following:

 

(i).
the parties having completed a due diligence investigation the results of which are satisfactory to the parties their sole discretion;

 

(ii).
at the time of the Transaction, Pulse will have no liabilities, contingent or otherwise, unless such liabilities have been specifically
agreed to by NVOS in writing;

 

(iii).
Pulse will not be debarred or lose its status with any third-party or government payor/services for the provision of pharmacy
services because of the Transaction;

 

(iv).
Pulse will have received all regulatory approvals required to complete the Transaction;

 

    	 	 	 

    	 

    

 

(v).
the parties agree to cooperate to prepare for filing the necessary current reports with the Securities and Exchange Commission
with respect to the Transaction, including a Form 8-K, within the regulatory required time limits following the closing of the
Transaction

 

(vi).
the representations and warranties contained herein shall be true and correct in all material respects as of the closing of the
Transaction; and

 

(vii).
no material adverse change shall have occurred in the business, assets, liabilities, results, financial condition, affairs or
prospects of Pulse from the date hereof to the closing of the Transaction.

 

6.
Adjustment of Officers and Directors: At the closing of the Transaction, Pulse will appoint a director to each of the NHL
and the NVOS boards as described above.

 

7.
Confidentiality: Each party agrees that, subject to compliance with applicable laws, it will keep confidential, and not release
to any other person, this proposal, the contents of this non-binding Letter of Intent and any of the proprietary business, technical
or other information obtained by it during its due diligence inquiries and any related negotiations. Each party’s obligations
in this respect shall survive the closing of the Transaction or any termination of the proposed Transaction between the parties
or the termination of this LOI.

 

8.
Disclosure: No public announcement concerning the Transaction contemplated herein or the status of the discussions between
the parties hereto shall be made by either party unless and until the same has been approved by both parties hereto, unless such
disclosure is required by any government laws, rules or regulations, by any government regulatory authorities or any stock exchange
having jurisdiction over either party provided prior written notice is provided to the other party respecting such disclosure
or public announcement and such party has been provided reasonable opportunity to review and comment on the proposed disclosure.

 

9.
Costs: The parties will each be solely responsible for and bear their own respective expenses, including, without limitation,
expenses of legal counsel, accountants, and other advisors, incurred at any time in connection with pursuing or consummating the
Transaction. Each party’s obligations in this respect shall survive the closing of the Transaction or any termination of
the proposed Transaction between the parties. It is expressly understood that both parties’ counsel will be together, responsible
for preparing the documents required to complete the Transaction including the filing statement required to be filed with the
Exchange in connection with the Transaction.

 

10.
Exclusivity: The parties hereby agree that until the Termination Date (as defined below) and the date the parties enter into
the Definitive Agreement, that neither party, their respective directors, officers, agents and representatives will not, directly
or indirectly:

 

(i)
solicit, initiate or encourage the initiation of any expression of interest, inquiries or proposals regarding, constituting or
that may reasonably be expected to lead to any merger, amalgamation, take-over bid, tender offer, arrangement, recapitalization,
liquidations, dissolution, share exchange, sale of material assets involving the parties or a proposal or offer to do so (the
“Acquisition Proposal”) (including without limitation, any grant of an option or other right to take any such
action);

 

(ii).
participate in any discussions or negotiations regarding an Acquisition Proposal;

 

(iii).
accept or enter into, or propose publicly to accept or enter into, any agreement, letter of intent, memorandum of understanding
or any arrangement in respect of an Acquisition Proposal; and

 

(iv)
otherwise cooperate in any way, assist or participate in, facilitate or encourage any effort or attempt by any person to do any
of the foregoing.

 

    	 	 	 

    	 

    

 

11.
Binding Effect: The consummation of the Transaction is subject to the entry of the Definitive Agreement. The Definitive Agreement
is subject to the board approval of each of the parties.

 

12.
Termination: If the Definitive Agreement is not negotiated and executed by both parties on or before February 12th, 2019 or
such other date as agreed to by the parties, (the “Termination Date”) the terms of this LOI will be of no further
force or effect except for Section 7 (Confidentiality), Section 9 (Costs) and Section 13 (Governing Laws). Section 7 and Section
13 will remain in effect for a period of one (1) year following the date this LOI is terminated.

 

13.
Governing Laws: This Letter of Intent will be governed by and be construed in accordance with the laws of the Province of
Ontario and the federal laws of Canada applicable therein. The parties agree that any dispute arising out of or relating to this
LOI shall be subject to the exclusive jurisdiction of the courts in and for the Province of Ontario and each party agrees to submit
to the personal and exclusive jurisdiction and venue of such courts. Governing law and jurisdiction regarding the Definitive Agreement
shall be negotiated between and agreed to by the parties and set out in the Definitive Agreement.

 

If
the terms outlined above are acceptable to you please sign and date this Letter in the space provided below and return a signed
copy to the undersigned.

 

	 	Very
    truly yours,
	 	 	 
	 	By:	/s/
    Robert Mattacchione
	 	 	Robert
    Mattacchione
	 	 	Novo
    Integrated Sciences, CEO
	 	 	Novo
    Healthnet Limited, Chairman
	 	 	 
	 	ACKNOWLEDGED
    AND AGREED to on: February 4, 2019
	 	 	 
	 	By:	/s/
    Martin Kusmirek
	 	 	Martin
    S. Kusmirek, President
	 	 	Pulse
    Rx Inc. o/a Pulse Rx LTC Pharmacy

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]